Traxion Sab De Cv Ord Shs GRPOF

RE:RE:RE:RE:RE:Edward Miller facebook

[TripleEm]

LeafRider wrote:

PCR1917 wrote:

SelfMade wrote: No it hasn’t changed and we should be finding out anyday now who the major pharmaceutical player that they teamed up with is. Lots happening in October from what I understand. Major developments taking place. Time to finally see some serious SP appreciation 

What are your sources to pretend to have more info than Edward Miller himself?

It is my understanding that IR has stated that sales "would commence in 2018 with this partnership, and the announcement will come in 2019"... So I am curious as to why it's so important to hold this NR back from shareholders at a time when visibility is key.

This is what I Believe:

1. Tetra has the NRs over the next 3-4 months that will help us do our thing without this announcement... So, if the partnering company feels they "need" to hold back on the timing of the NR so be it. However, this partnership better not be exclusive to this pharma partner, because if it is and we're limiting our own exposure at the onset of the market simply to please these clowns' timelines, then Guy isn't thinking straight at the CEO position. They've stated it would be announced at legalization and I expect them to either public announce the change here, or announce it by legalization!! People don't like the sliding schedules, but if there is a reason for it then get it out there to spare us all from the bashers BS.

2. It's likely Tetra's products will be hitting the shelf and sales will be realized in Q4-2018, because lets face it this pharma parter is the one distributing, labelling, and marketing the product line. The partnering company simply doesn't want to announce the deal for "strategic reasons."

3. Hopefully Tetra isn't trying to hold this back to try and raise more capital at a lower level, because it starts to feel like we're constantly held back and momentum killing selling into every good news event is to simply line the pockets of those committed to Private Placements or Bought-deal financings. Now if I'm Paradigm I'd be pi$$ed at this situation, either that or they are the ones behind it and will setup for another large share and warrants capital raise at much lower levels than where we deserve to be.

Lastly, I believe in the direction Tetra is going with all of this, and I trust they are being honest with the process. However, this is one area they need to clear up for shareholders, because it's clear different people have different expecations, myself included. Will some of us need to find some patience, and wait for this milestone, most likely based on what Mr. Miller has told those inquiring about this. JMHO

This might give a little bit more of an insight as to why they are waiting for the release of the distribution partener, as to my understanding, the Ford company is just the quality and packaging part of this puzzle to aquire the DIN.

Letter of Intent for a co-development and distribution partnership with the same privately held company in the specialty healthcare market. The company has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to more than 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners.

Partnership highlights

• In order to maximize both marketing and revenue impact, Tetra and its partner have agreed to launch all products at the same time, once the regulatory framework has been established by Health Canada following the legalization of cannabis. This includes cannabinoid-based as well as non-cannabinoid-based products. Both companies are confident that this strategy will solidify the brand awareness of Tetra's partner in this new product line. The timing of the original LOI was for the commencement of revenue in Q1 2018. Tetra and its partner are now revising that date to Q4 2018.
• Both Tetra and its partner will agree to a clinical trial plan, with Tetra owning and maintaining the right to use the data gathered from the trial(s) for its own regulatory and commercial efforts in its own, non-competitive Fields of Use.
• Tetra will develop a line of private label products for its partner, the products will be distributed under the partner's brand.

Read more at https://www.stockhouse.com/news/press-releases/2018/03/08/tetra-bio-pharma-signs-co-development-and-distribution-partnership-term-sheet#h3P3GrVmZtMmvZVx.99

JMO, GLTA...

GO TETRA GO>>>